Compare IPGP & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | ARQT |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.2B |
| IPO Year | 2000 | 2020 |
| Metric | IPGP | ARQT |
|---|---|---|
| Price | $72.91 | $31.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $124.14 | $39.13 |
| AVG Volume (30 Days) | 302.3K | ★ 2.2M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 117.85 | 88.79 |
| EPS | ★ 0.16 | 0.03 |
| Revenue | ★ $1,003,777,000.00 | $376,072,000.00 |
| Revenue This Year | $11.84 | $43.21 |
| Revenue Next Year | $9.07 | $29.18 |
| P/E Ratio | ★ $444.06 | $1,045.67 |
| Revenue Growth | 2.73 | ★ 91.34 |
| 52 Week Low | $68.27 | $19.30 |
| 52 Week High | $155.82 | $33.30 |
| Indicator | IPGP | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 66.30 |
| Support Level | $69.41 | $23.42 |
| Resistance Level | $81.08 | N/A |
| Average True Range (ATR) | 3.06 | 1.54 |
| MACD | -0.38 | 0.51 |
| Stochastic Oscillator | 40.02 | 82.43 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.